- On 27 June 2026, Liquidia Corporation was removed from several Russell benchmarks, including the Russell 3000E, Russell 3000E Growth, Russell Microcap and Russell Microcap Growth Indexes, following the annual index reconstitution.
- This withdrawal from multiple Russell indexes may alter the mix of investors exposed to Liquidia, as index-linked funds and benchmark-aware managers reassess their positions.
- We’ll now explore how Liquidia’s removal from multiple Russell indexes might influence its existing investment narrative around pulmonary hypertension therapies.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
Liquidia Investment Narrative Recap
To own Liquidia, you need to believe in the long term role of inhaled treprostinil therapies like YUTREPIA in pulmonary hypertension and related lung diseases, and in the company’s ability to manage ongoing litigation and regulatory complexity. The recent removal from several Russell indexes may shuffle shorter term shareholder mix, but does not appear to materially change the key near term catalyst around YUTREPIA’s commercialization or the central risk tied to legal outcomes and payer economics.
The most relevant recent development alongside the Russell changes is Liquidia’s June 2026 inclusion in multiple S&P benchmarks, including the S&P 600 Health Care and S&P Composite 1500. This new index exposure could partly offset the loss of Russell index-linked holders, while the main business catalysts still center on YUTREPIA’s clinical data presentations, payer access, and the progression of L606 as a potential follow on pulmonary hypertension asset.
Yet beneath the index reshuffling, one risk that investors should be aware of is how any adverse treprostinil litigation outcome could...
Read the full narrative on Liquidia (it's free!)
Liquidia's narrative projects $1.4 billion revenue and $665.8 million earnings by 2029. This requires 68.6% yearly revenue growth and about a $643.5 million earnings increase from $22.3 million today.
Uncover how Liquidia's forecasts yield a $72.38 fair value, a 11% downside to its current price.
Exploring Other Perspectives
While Russell index removal highlights one set of concerns, the most cautious analysts were already modeling revenue of about US$556,000,000 and earnings near US$23,400,000 by 2028, underscoring how much more pessimistic their expectations were compared with more optimistic views before this latest index shift potentially reshapes the story again.
Explore 5 other fair value estimates on Liquidia - why the stock might be worth less than half the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Liquidia research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Liquidia research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Liquidia's overall financial health at a glance.
No Opportunity In Liquidia?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com